- Home
- IMOS vs REPL Comparison
IMOS vs REPL Comparison
Compare IMOS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMOS
- REPL
- Stock Information
- Founded
- IMOS 1997
- REPL 2015
- Country
- IMOS Taiwan
- REPL United States
- Employees
- IMOS N/A
- REPL N/A
- Industry
- IMOS Semiconductors
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- IMOS Technology
- REPL Health Care
- Exchange
- IMOS Nasdaq
- REPL Nasdaq
- Market Cap
- IMOS 679.2M
- REPL 780.3M
- IPO Year
- IMOS N/A
- REPL 2018
- Fundamental
- Price
- IMOS $18.49
- REPL $10.14
- Analyst Decision
- IMOS
- REPL Strong Buy
- Analyst Count
- IMOS 0
- REPL 6
- Target Price
- IMOS N/A
- REPL $17.50
- AVG Volume (30 Days)
- IMOS 24.0K
- REPL 794.9K
- Earning Date
- IMOS 02-20-2025
- REPL 02-06-2025
- Dividend Yield
- IMOS 6.10%
- REPL N/A
- EPS Growth
- IMOS 7.03
- REPL N/A
- EPS
- IMOS 0.07
- REPL N/A
- Revenue
- IMOS $724,842,895.00
- REPL N/A
- Revenue This Year
- IMOS $11.63
- REPL N/A
- Revenue Next Year
- IMOS $6.29
- REPL $300.41
- P/E Ratio
- IMOS $12.75
- REPL N/A
- Revenue Growth
- IMOS 13.31
- REPL N/A
- 52 Week Low
- IMOS $17.70
- REPL $4.92
- 52 Week High
- IMOS $32.19
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- IMOS 44.05
- REPL 32.06
- Support Level
- IMOS $17.70
- REPL $10.00
- Resistance Level
- IMOS $18.60
- REPL $11.20
- Average True Range (ATR)
- IMOS 0.34
- REPL 0.84
- MACD
- IMOS 0.01
- REPL -0.20
- Stochastic Oscillator
- IMOS 51.97
- REPL 3.93
About IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. The Company derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.